Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues

Journal of Virology

Volumn 87, Issue 16, 2013, Pages 8952-8961

  Massud, Ivana ^a   Aung, Wutyi ^a   Martin, Amy ^a   Bachman, Shanon ^a   Mitchell, James ^a   Aubert, Rachael ^a   Tsegaye, Theodros Solomon ^a   Kersh, Ellen ^a   Pau, Chou Pong ^a   Heneine, Walid ^a   García Lerma, J Gerardo ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MARAVIROC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TISSUE LEVEL; FEMALE; IN VITRO STUDY; INTRACELLULAR TRANSPORT; LYMPHOID TISSUE; MACACA; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RECTUM; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VAGINA; VIRUS INHIBITION; VIRUS RELEASE; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTI-RETROVIRAL AGENTS; CHEMOPREVENTION; CYCLOHEXANES; FEMALE; INTESTINAL MUCOSA; MACACA; MALE; PLASMA; RECTUM; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TREATMENT FAILURE; TRIAZOLES;

EID: 84881255827     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01204-13     Document Type: Article

References (46)

1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, EmmanuelOgier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C, Partners PrEP Study Team. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367:399-410.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV, the iPrEx Study Team. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-2599.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, TDF2 Study Group. 2012. Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367:423-434.
4. Garcia-Lerma JG, Heneine W. 2012. Animal models of antiretroviral prophylaxis for HIV prevention. Curr. Opin. HIV AIDS 7:505-513.
5. Perry CM. 2010. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Drugs 70:1189-1213.
6. Frentz D, Boucher CA, van de Vijver DA. 2012. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 14:17-27.
7. Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, Spacek MB, Heidt PE, Cohen MS, Kashuba AD. 2011. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J. Infect. Dis. 203:1484-1490.
8. Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, Tressler R, Worsley J, Kashuba AD. 2009. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J. Acquir. Immune Defic. Syndr. 51:546-553.
9. Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R. 2010. Oral preexposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 21:e15257. doi:10.1371/journal.pone.0015257.
10. Neff CP, Kurisu T, Ndolo T, Fox K, Akkina R. 2011. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized mice. PLoS One 6:e20209. doi:10.1371 /journal.pone.0020209.
11. Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP. 2010. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 coreceptor. J. Infect. Dis. 202:739-744.
12. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, Springer MS, Moore JP. 2005. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438:99-102.
13. Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJ, JP M. 2005. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat. Med. 11:1293-1294.
14. Haase AT. 2011. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu. Rev. Med. 62:127-139.
15. Hu J, Gardner MB, Miller CJ. 2000. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74:6087-6095.
16. Ribeiro Dos Santos P, Rancez M, Prétet JL, Michel-Salzat A, Messent V, Bogdanova A, Couëdel-Courteille A, Souil E, Cheynier R, Butor C. 2011. Rapid dissemination of SIV follows multisite entry after rectal inoculation. PLoS One 6:e19493. doi:10.1371/journal.pone.0019493.
17. Poonia B, Wang X, Veazey RS. 2006. Distribution of simian immunodeficiency virus target cells in vaginal tissues of normal rhesus macaques: implications for virus transmission. J. Reprod. Immunol. 72:74-84.
18. García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong M, Masciotra S, Luo W, Kim C, Adams DR, Monsour M, Lipscomb J, Johnson JA, Delinsky D, Schinazi RF, Janssen R, Folks TM, Heneine W. 2008. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 5:e28. doi: 10.1371/journal.pmed.0050028.
19. Otten RA, Adams DR, Kim CN, Jackson E, Pullium JK, Lee K, Grohskopf LA, Monsour M, Butera S, TM F. 2005. Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J. Infect. Dis. 19:164-173.
20. Radzio J, Aung W, Holder A, Martin A, Sweeney E, Mitchell J, Bachman S, Pau C, Heneine W, García-Lerma JG. 2012. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One 7:e50632.
21. Subbarao S, RA Otten RA, Ramos A, Kim C, Jackson E, Monsour M, Adams DR, Bashirian S, Johnson J, Soriano V, Rendon A, Hudgens MG, Butera S, Janssen R, Paxton L, Greenberg AE, Folks TM. 2006. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J. Infect. Dis. 194:904-911.
22. Kim C, Adams D, Bashirian S, Butera S, Folks T, Otten R. 2006. Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre-clinical interventions in non-human primates. J. Med. Primatol. 35:210-216.
23. Mordenti J. 1986. Man versus beast: pharmacokinetic scaling in mammals. J. Pharm. Sci. 75:1028-1040.
24. Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, Martin A, Kuklenyik Z, Holder A, Lipscomb J, Pau CP, Barr JR, Hanson DL, Otten R, Paxton L, Folks TM, Heneine W. 2010. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci. Transl. Med. 2:14ra14.
25. Kozlowski PA, Lynch RM, Patterson RR, Cu-Uvin S, Flanigan TP, Neutra MR. 2000. Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J. Acquir. Immune Defic. Syndr. 24:297-309.
26. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C. 1999. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284:816-819.
27. Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E. 2005. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 11:1170-1172.
28. Winters MA, Van Rompay KK, Kashuba AD, Shulman NS, Holodniy M. 2010. Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. Antimicrob. Agents Chemother. 10:4059-4063.
29. Rosario MC, Jacqmin P, Dorr P, James I, Jenkins TM, Abel S, van der Ryst E. 2008. Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIVpositive patients. Br. J. Clin. Pharmacol. 65(Suppl 1):86-94.
30. + T cells. Science 270:1811-1815.
31. Mueller A, Mahmoud NG, Goedecke MC, McKeating JA, Strange PG. 2002. Pharmacological characterization of the chemokine receptor, CCR5. Br. J. Pharmacol. 135:1033-1043.
32. Zheng Q, Ruone S, Switzer WM, Heneine W, Garcia-Lerma JG. 2012. Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis. Retrovirology 9:40.
33. García-Lerma JG, Aung W, Cong ME, Zheng Q, Youngpairoj AS, Mitchell J, Holder A, Martin A, Kuklenyik S, Luo W, Lin CY, Hanson DL, Kersh E, Pau CP, Ray AS, Rooney JF, Lee WA, Heneine W. 2011. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J. Virol. 85:6610-6617.
34. Rossi R, Lichtner M, Sauzullo I, Mengoni F, Marocco R, Massetti AP, Mastroianni CM, Vullo V. 2010. Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc. J. Acquir. Immune Defic. Syndr. 54:e13-e14.
35. Rossi R, Lichtner M, De Rosa A, Sauzullo I, Mengoni F, Massetti AP, Mastroianni CM, Vullo V. 2011. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin. Exp. Immunol. 166: 184-190.
36. + mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J. Virol. 75:8390-8399.
37. Malcolm RK, Forbes CJ, Geer L, Veazey RS, Goldman L, Johan Klasse P, Moore JP. 2012 Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J. Antimicrob. Chemother. [Epub ahead of print.]
38. + T cell recovery: a randomized trial. Blood [Epub ahead of print.]
39. + T cell depletion and viral replication in SIV infection. Science 280:427-431.
40. Jospeh S, Ping L, Anderson J, Kincer L, Morris L, Hahn B, Williamson C, Swanstrom R. 2012. Heterosexual transmission selects for virus that requires high levels of CD4 to enter cells and is more homogeneous in its sensitivity to CCR5 antagonists, abstr 61, p 100. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
41. Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee FH, Didigu CA, Berro R, Klasse PJ, Lee B, Moore JP, Shaw GM, Hahn BH, Doms RW. 2013. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J. Virol. 2013 87:2401-2411.
42. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM. 2012. Emtricitabine-tenofovir concentrations and preexposure prophylaxis efficacy in men who have sex with men. Sci. Transl. Med. 4:151ra125.
43. Powers KA, Poole C, Pettifor AE, Cohen MS. 2008. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect. Dis. 8:553-563.
44. Napier C, Sale H, Mosley M, Rickett G, Dorr P, Mansfield R, Holbrook M. 2005. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem. Pharmacol. 71:163-172.
45. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
46. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371.